Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

ItalyBack to Italy

Clinical trials in Verona – page 36

434 clinical trials in Verona, Italy across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Verona at a glance
434
clinical trials
  • Research sites2
Type of trial
Recruitment status
Quick filters

434 trials in Verona

Open in trial search

Non-small cell lung cancer

Not recruiting

Study of Belrestotug and Dostarlimab for Patients with Untreated Advanced Non-Small Cell Lung Cancer

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Dostarlimab
  • Sponsor:Glaxosmithkline Research & Development Limited

Study on Langerhans Cell Histiocytosis Treatment in Children and Adolescents Using Cladribine, Prednisolone, and Cytarabine

Not recruiting
Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Alemtuzumab
  • Sponsor:St. Anna Childrens Cancer Research Institute GmbH

Systemic mastocytosis+1

Not recruiting

Study of Avapritinib for Patients with Indolent Systemic Mastocytosis Not Adequately Managed by Standard Therapy

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Avapritinib
  • Sponsor:Blueprint Medicines Corp.

Neoplasm

Not recruiting

Study of MCLA-129 with Chemotherapy and Osimertinib for Patients with Advanced Non-Small Cell Lung Cancer and Other Solid Tumors

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Genmab A/S

Cystic fibrosis

Not recruiting

Long-term safety and efficacy study of elexacaftor/tezacaftor/ivacaftor treatment in people with cystic fibrosis who have non-F508del genetic mutations

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years
  • Substances:Elexacaftor
  • Sponsor:Vertex Pharmaceuticals Inc.

Metastatic malignant melanoma

Not recruiting

Study of Tucidinostat and Nivolumab for Patients with Advanced Melanoma Not Treated with PD-1 or PD-L1 Inhibitors

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Huyabio International LLC

Non-small cell lung cancer

Not recruiting

Study on the Safety and Effectiveness of Volrustomig with a Drug Combination for Patients with Solid Tumors

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:AstraZeneca AB

Acute lymphocytic leukaemia

Not recruiting

Study on Imatinib and Chemotherapy Combination for Children with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years
  • Substances:Crisantaspase
  • Sponsor:Universita Degli Studi Di Milano Bicocca

Anaplastic large cell lymphoma T- and null-cell types+2

Not recruiting

Study of Romidepsin and Drug Combination for Young Patients with Peripheral T-Cell Lymphomas Before Stem Cell Transplantation

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:Romidepsin
  • Sponsor:Fondazione Italiana Linfomi Ets

Asthma

Not recruiting

Study on Reducing Asthma Medication with Tezepelumab in Patients Aged 12 to 80 with Severe Asthma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Tezepelumab
  • Sponsor:AstraZeneca AB

Non-small cell lung cancer

Not recruiting

Study on Datopotamab Deruxtecan and Osimertinib for Patients with Advanced Non-Small Cell Lung Cancer After Osimertinib Treatment

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:AstraZeneca AB

Mantle cell lymphoma stage II+2

Not recruiting

Study on Ibrutinib and Drug Combination for Patients with Generalized Mantle Cell Lymphoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:Ibrutinib
  • Sponsor:Klinikum der Universitaet Muenchen AöR

Other cities in Italy

The busiest research cities in the country

All 237 cities in Italy

Clinical research in Verona

What the registry says about research in the country

01 Neurological Disorders

Innovative research focusing on acute ischemic stroke treatment and neurological conditions including narcolepsy and Dravet Syndrome. Studies evaluate new therapeutic approaches for improving patient outcomes and managing symptoms.

  • Stroke Treatment Optimization
  • Sleep Disorders Management
  • Seizure Control

Multiple trials exploring novel medications and treatment combinations for better patient care.

02 Oncology Research

Comprehensive studies targeting various cancers including gastric cancer, Merkel cell carcinoma, and metastatic colorectal cancer. Research focuses on innovative treatment combinations and targeted therapies.

  • Advanced Solid Tumors
  • Hematological Malignancies
  • Immunotherapy Approaches

Trials investigating novel drug combinations and personalized treatment strategies.

03 Autoimmune Conditions

Clinical investigations into Sjögren's Syndrome, systemic sclerosis, and other autoimmune disorders. Studies evaluate new biological treatments and their long-term effectiveness.

  • Connective Tissue Disorders
  • Chronic Inflammatory Conditions
  • Novel Therapeutic Approaches

Research focusing on improving quality of life and disease management for patients.

Back to ItalyAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.